MSC vs HSCT for Lupus (SLE): what the registries show
For Lupus (SLE), the registry holds 21 MSC records against 17 HSCT records. MSC carries the larger research programme; neither column is a head-to-head efficacy result. Snapshot 2026-08-29.
Side by side
| Metric | MSC | HSCT |
|---|---|---|
| Registered studies | 21 | 17 |
| Recruiting now | 3 | 2 |
| Phase 3 or 4 records | 1 | 1 |
| Completed | 6 | 5 |
| Stopped early | 0 | 6 |
| Countries with sites | 7 | 4 |
| Median planned enrolment | 20 | 16 |
| First registration year | 2,007 | 2,000 |
The condition underneath the comparison
Systemic lupus erythematosus is autoimmunity against nuclear antigens with relapsing multi-organ involvement. Two lines exist: mesenchymal immunomodulation, and immune reset through haematopoietic transplantation or CAR-T, the latter producing the most striking recent case series in autoimmunity. Those are radically different risk-benefit propositions.
MSC: what it is
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
HSCT: what it is
Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.
Maturity difference
MSC has 1 Phase 3/4 records and 6 completed studies; HSCT has 1 and 5. Where both sit early on the ladder, the honest answer to "which works better" is that registrations cannot tell you.
Leading MSC studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07041801 — Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells | Phase 1, Phase 2 | Recruiting | 58 | Shenzhen Beike Bio-Technology Co., Ltd. | 2025-06-28 |
| NCT06058078 — RY_SW01 Cell Injection Therapy in Active Lupus Nephritis | Phase 2 | Recruiting | 60 | Jiangsu Renocell Biotech Company | 2023-08-17 |
| NCT03673748 — Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells | Phase 2 | Recruiting | 20 | Red de Terapia Celular | 2022-12-27 |
| NCT05631717 — The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN | Phase 3 | Unknown | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer | 2022-10-01 |
| NCT06888973 — Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases | Phase 1, Phase 2 | Enrolling By Invitation | 200 | National Institute of Blood and Marrow Transplant (NIBMT), P | 2025-02-01 |
Leading HSCT studies
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT05029336 — Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases | Phase 2 | Recruiting | 20 | Stephan Grupp MD PhD | 2026-03 |
| NCT05508009 — Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor | Phase 1, Phase 2 | Recruiting | 12 | Alice Bertaina | 2023-01-10 |
| NCT05063513 — Autologous Stem Cell Transplantation: International Lupus Trial | Phase 2, Phase 3 | Withdrawn | n/a | European Society for Blood and Marrow Transplantation | 2009-07 |
| NCT00659217 — Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis | Phase 1, Phase 2 | Unknown | 20 | Organ Transplant Institute, China | 2008-05 |
| NCT00750971 — Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST) | Phase 2 | Unknown | 30 | Charite University, Berlin, Germany | 2008-08 |
The honest comparison
Head-to-head trials putting these two approaches in the same protocol are rare or absent for most conditions. Comparing counts from separate registry queries shows where research effort went — driven by cost, regulation and sponsor interest as much as by biology. Anyone presenting one column of this table as proof of superiority is overreading it.
Frequently asked
Is MSC better than HSCT for Lupus (SLE)?
The registries cannot answer that. They show research volume and maturity, not comparative effectiveness: 21 vs 17 registered records (2026-08-29).
Which has more late-stage research for Lupus (SLE)?
MSC: 1 Phase 3/4 records. HSCT: 1.
Can a clinic offer both?
Some do, which is itself worth questioning — a provider offering every modality for every condition is describing a business model, not a treatment rationale.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.